Literature DB >> 2985245

Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells.

E Ben-Hur, C C Chen, M M Elkind.   

Abstract

3-Aminobenzamide, a specific inhibitor of poly(adenosine diphosphoribose) synthesis, has been shown to enhance the response of mammalian cells to ionizing radiation and alkylating agents. Observations such as these usually have been taken to be an indication of the involvement of poly(adenosine diphosphoribose) in the repair of DNA damage. It has been reported that some inhibitors of adenosine diphosphoribosyl transferase (ADPRT) affect cell viability, glucose metabolism, and DNA synthesis when present at low concentrations in the growth medium for extended periods (e.g., lymphoid cells exposed to a few millimolar for 24 h [Milam, K. M., and Cleaver, J. E. Science (Wash. DC), 223: 589, 1984]). The latter report questioned previous interpretations of radiation results based on the use of ADPRT inhibitors which enhance cell killing. We have studied the enhanced radiation lethality of Chinese hamster cells using higher concentrations of these inhibitors, but for shorter periods, in an effort to determine if metabolic perturbations are produced and if they are relatable to enhanced cell killing. The compounds used were 2-aminobenzamide, 3-aminobenzamide, 4-aminobenzamide, benzamide, and nicotinamide, compounds which show a large variation in their potency as inhibitors of ADPRT. It was found that none of the compounds was toxic at the highest doses used (20 mM for 2 h) and that, during a 2-h period, the potent inhibitor 3-aminobenzamide had little or no effect on DNA synthesis. Two h is long enough to yield a near-maximum radiosensitization with 3-aminobenzamide. Although glucose metabolism was affected to varying degrees (up to a 50% inhibition by 4-aminobenzamide in 2 h), there was no correlation between effectiveness in inhibiting ADPRT and effectiveness in inhibiting glucose metabolism. A correlation was observed, however, between the inhibitory potential of ADPRT and the enhancement of radiation response. When used for sufficiently short times, we conclude that the effects at even high concentrations of a potent inhibitor of ADPRT (e.g., 3-aminobenzamide) are consistent with an involvement of poly(adenosine diphosphoribose) synthesis in the expression of a radiation-induced end point like cell killing.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985245

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.

Authors:  Yong Tang; Hossein A Hamed; Andrew Poklepovic; Yun Dai; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2012-05-17       Impact factor: 4.436

Review 2.  Inhibitors and activators of ADP-ribosylation reactions.

Authors:  M Banasik; K Ueda
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

3.  PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.

Authors:  Esraa M Zakaria; Nabila N El-Maraghy; Ahmed F Ahmed; Abdelmonim A Ali; Hany M El-Bassossy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-21       Impact factor: 3.000

Review 4.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 5.  Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Authors:  N J Curtin
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

6.  PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.

Authors:  Laurence Booth; Nichola Cruickshanks; Thomas Ridder; Yun Dai; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2013-05       Impact factor: 4.742

7.  PARP1 Inhibitors: antitumor drug design.

Authors:  N V Malyuchenko; E Yu Kotova; O I Kulaeva; M P Kirpichnikov; V M Studitskiy
Journal:  Acta Naturae       Date:  2015 Jul-Sep       Impact factor: 1.845

8.  Blood flow modification by nicotinamide and metoclopramide in mouse tumours growing in different sites.

Authors:  D G Hirst; B Joiner; V K Hirst
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

9.  Enhancement of cyclophosphamide cytotoxicity in vivo by the benzamide analogue pyrazinamide.

Authors:  M R Horsman; D J Chaplin
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

10.  Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

Authors:  K J Bowman; A White; B T Golding; R J Griffin; N J Curtin
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.